India Services Sector Rebounds in January as New Business Gains Momentum: HSBC PMI Shows Growth 
Asian Markets Wobble as AI Fears Rattle Stocks, Oil and Gold Rebound 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Australia’s December Trade Surplus Expands but Falls Short of Expectations 
Oil Prices Slip as U.S.–Iran Talks Ease Supply Disruption Fears 
U.S. Stock Futures Edge Higher as Tech Rout Deepens on AI Concerns and Earnings 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Australia’s Corporate Regulator Urges Pension Funds to Boost Technology Investment as Industry Grows 
Thailand Inflation Remains Negative for 10th Straight Month in January 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Asian Currencies Trade Sideways as Dollar Stabilizes, Yen Weakens Ahead of Japan Election 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Sanofi's Exclusive Negotiations with Clayton Dubilier & Rice
Sanofi (NASDAQ: SNY) announced on Monday that it has entered exclusive negotiations to sell a 50% controlling stake in its consumer health division, Opella, to the U.S. private equity firm Clayton Dubilier & Rice (CD&R). This strategic move reflects Sanofi's ongoing efforts to optimize its portfolio and focus on core operations.
Valuation and Investment Details
The Opella business is valued at approximately €16 billion ($17.38 billion), equating to 14 times its expected EBITDA for 2024. Additionally, the French public investment bank, Bpifrance, is anticipated to acquire a stake of around 2%, further solidifying the financial backing of this transaction.
Transaction Timeline and Approvals
The proposed sale is subject to definitive agreements and customary statutory approvals. If all goes according to plan, the transaction is expected to close by the second quarter of 2025 at the earliest, marking a significant milestone for both Sanofi and CD&R.
As the negotiations progress, stakeholders will be closely monitoring the developments surrounding this transaction, given its potential impact on Sanofi's market position and future growth strategies.
